Pseudoarthrosis Treatment Market to Reach $1.37 Billion by 2034, Growing at 4.6% CAGR

Revenue from the global pseudoarthrosis treatment market is projected to reach US$ 879.4 million in 2024 and then grow at a compound annual growth rate (CAGR) of 4.6% from 2024 to 2034, according a recent industry analysis published by Fact.MR.

Expanding research and development into sophisticated medical devices to treat complex illnesses and continuous improvements in biocompatible materials—materials created especially for healing and fusing—are driving market expansion. Treatment for pseudoarthrosis is usually becoming highly expensive for individuals, depending on the severity. The market for pseudarthrosis treatments is apparently growing as a result of favorable government reimbursement programs in some nations.

Because of the quick advancements in the surgical and medical device sectors, North America dominates the industry. However, compared to other regions, South Asia and the Pacific are seeing a faster growth in the demand for pseudoarthrosis treatment.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10242

Key Insights from the Market Study

• The global pseudarthrosis treatment market is anticipated to reach $1.37 billion by the end of 2034.
• North America is expected to account for 1% of the global market share, with projected revenue of $630.6 million by 2034.
• Sales of bone growth stimulators are estimated to generate $258.9 million in revenue in 2024.
• The market in India is forecasted to grow at a 7.8% CAGR through 2034.
• Over-the-counter (OTC) purchases are projected to capture 1% of the global market share by 2034.
• The United States market is predicted to reach $541.9 million in revenue by 2034.
• The Western Europe market is set to achieve a value of $240.7 million by the end of 2034.

Leading Companies Fueling Innovation in the Market for Pseudarthrosis Treatments:

The industry is being driven by major players such as AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Bioventus, Cipla, Daiichi Sankyo, Eli Lilly, Eurofarma, Fresenius, GlaxoSmithKline, Grunenthal, Hikma Pharmaceuticals, Johnson & Johnson, Julphar, Medtronic, Novartis, NuVasive, Orthofix, Pharco Pharmaceuticals, Roche, Sanofi, Stryker, Sun Pharma, Tabuk Pharmaceuticals, Takeda, Teva Pharmaceuticals, UCB, Zimmer Biomet, etc.

Growing Preference for Stimulators of Bone Growth

Since bone growth stimulators are more efficient and less intrusive, they are usually thought to be suitable for treating pseudoarthrosis. These devices use ultrasonic therapy or electrical stimulation to promote cell function and generate growth factors that aid in bone healing. When traditional therapies like casting or surgery don't work, bone growth stimulators can be especially helpful.

They lessen the risks involved with invasive procedures when applied externally. They also help the patient move around a little while receiving treatment.

Pseudarthrosis Treatment Industry Updates

• Orthofix Medical Inc., a global leader in spine and orthopedic solutions, published findings in December 2023 from a prospective, multicenter study on using pulsed electromagnetic field stimulation (PEMF) as a post-operative therapy for lumbar spinal fusion in patients at risk of pseudarthrosis. The study, featured in the International Journal of Spine Surgery, highlighted that patients treated with the SpinalStim bone growth device showed high rates of successful fusion and significant improvements in pain relief, functionality, and quality of life, even with risk factors for pseudarthrosis.

• In December 2022, the U.S. Food and Drug Administration (FDA) approved a new indication for the CAVUX Facet Fixation System (FFS) developed by Providence Medical Technology. The FFS, an innovative device combining an integrated cage and screw system, is designed to stabilize facet joints prior to fusion. The approval applies to patients needing autogenous or allogenic bone graft revision for anterior pseudarthrosis at a single level from C3 to C7.

Why is Demand for Pseudarthrosis Treatment Growing Globally?

The rise in demand for pseudarthrosis treatments is driven by advancements in biologics, bone growth stimulators, antibiotics, stem cell therapies, and other innovative approaches. These developments have significantly improved the safety and effectiveness of pseudarthrosis treatments. For example, using synthetic grafts and biologics in advanced bone grafting techniques enhances bone healing and integration, encouraging more patients to adopt these solutions and fueling market growth.

The demand is further amplified by the increasing prevalence of pseudarthrosis, often caused by high-impact trauma, osteoporosis, and other bone-related disorders. Conditions such as osteopenia contribute to a higher incidence of non-unions, where fractured bones fail to heal properly, necessitating specialized interventions.

As the number of patients affected by this debilitating condition continues to rise, the need for more advanced medications and treatments grows, driving the global expansion of the pseudarthrosis treatment market.

Country-specific Perspectives

According to Fact.MR's forecast, North America is expected to hold a 45.3% market share in 2024 and grow to 46.1% by 2034 for pseudoarthrosis treatments. This stance is mostly due to ongoing innovation in the domains of surgical methods and medical technology. Western

From 2024 to 2034, the demand for pseudoarthrosis treatment in Europe is expected to increase at a 3.2% CAGR. The demand for pseudoarthrosis therapy is expected to grow at a 6.4% CAGR through 2034, which means that even though the South Asia & Pacific area is only expected to hold a 7.3% market share, it will present significant potential for leading firms.

The United States is expected to account for 87.5% of North American income in 2024. The US is one of the nations in the world with the highest per capita healthcare spending. The nation is renowned worldwide for its substantial investments in cutting-edge medical care, including pseudoarthrosis. The United States' financial ability to create and adopt new medical technologies is simplifying and enhancing the results of treating pseudoarthrosis, which ultimately draws patients from other nations.

Category-Specific Perspectives

The market is divided into three age groups: children, adults, and senior citizens. In 2024, adults between the ages of 30 and 60 are expected to make up 71.4% of the total revenue. Adults with high-impact injuries, especially those engaged in physically demanding occupations, sports, and other activities, are mostly responsible for pseudoarthrosis.

Bone growth stimulators are typically seen to be the best option for treating pseudoarthrosis since they are more efficient and less intrusive. These devices use electrical stimulation or ultrasound therapy to stimulate cell activity and produce growth factors that promote bone repair.

 Hospitals are typically chosen by patients with pseudoarthrosis issues. The majority of hospitals have the sophisticated technology and specialist operating rooms required to perform challenging procedures like bone grafting and spinal fusion, which are necessary to treat pseudoarthrosis.

Patients with complex nonunion cases are more likely to choose hospitals with multidisciplinary teams of specialists, such as orthopedic surgeons, radiologists, and physical therapists, who collaborate to provide patients with comprehensive care until full recovery.

Competitive Landscape

Leading companies in the pseudarthrosis treatment market are focused on reducing the complexity of related procedures. Continuous advancements in devices, as well as innovations in biologics, antibiotics, stem cell therapies, and bone growth stimulators, are enhancing treatment outcomes for pseudarthrosis.

• In December 2023, Orthofix Medical Inc., a global leader in spine and orthopedic treatments, unveiled new findings from a multicenter, prospective study. The study evaluated the use of pulsed electromagnetic field stimulation (PEMF) as a post-operative therapy for lumbar spinal fusion in patients at risk of pseudarthrosis. Results, published in the International Journal of Spine Surgery, revealed that patients treated with the SpinalStim bone growth device achieved high rates of successful fusion alongside significant improvements in pain relief, functionality, and quality of life, even with associated risk factors.

• In December 2022, the U.S. Food and Drug Administration (FDA) approved a new application for the CAVUX Facet Fixation System (FFS) by Providence Medical Technology. This innovative device, featuring an integrated cage and screw system, is designed to stabilize facet joints during fusion procedures. The approval applies to patients requiring autogenous or allogenic bone graft revisions for anterior pseudarthrosis at a single level between C3 and C7.

The latest market report by Fact.MR offers comprehensive insights into the pricing strategies of key players in the pseudarthrosis treatment industry, global sales growth, production capacities, and anticipated technological advancements shaping the market’s future.

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com